Characteristics of included literature
| Author/year/ref | Country | Sample size (T/C) | Age (T/C) | Drug concentration (T/C) | Frequency of administration (T/C) | Intervention measure (T/C) | Intervention duration | Objective sign baseline (mean±SD, T/C) | Subjective symptom baseline (mean±SD, T/C) | Outcome measures |
| Zhang X/ 201412 | China | 8/8 | 12.56±8.97 | 0.1% | One drop/time, twice daily | Tacrolimus/ placebo | 4 W | 17.3750±5.31507/ 19.0000±5.57375 | 8.3750±2.24722/ 8.3125±2.21265 | Signs, symptoms |
| Pucci N/ 201513 | Italy | 30/30 | 9.05±2.12 | 0.1%/1% | One drop/time, 3 times daily | Tacrolimus/ cyclosporine A | 3 W | 6.016±1.133/ 6.000±1.121 | 6.3±3.415/ 6.566±3.349 | Signs, symptoms, side effects, quality of life score, |
| Zanjani H/ 201714 | Iran | 20/20 | 10.9±3.4/ 11.3±5.4 | 0.005%/ 1 000 000 IU/mL | Two drops/time | Tacrolimus +placebo/ interferon α-2b+placebo | NA | 7.7±1.2/ 8.9±1.2 | 9.6±0.8/ 9.7±0.9 | Signs, symptoms, side effects |
| Kumari R/ 201715 | India | 16/16 | 8.06±1.94/ 7.12±1.66 | 0.03%/0.05% | Twice daily+4 times daily/ 4 times daily+twice daily | Tacrolimus +placebo/ cyclosporine +placebo | 6 W | 4.88±1.5/ 4.5±1.15 | 7.06±2.59/ 7.75±2.90 | Signs, symptoms, side effects, recurrence rate |
| Xiang Q/ 201816 | China | 28/27 | 10.86±2.98/ 10.93±3.51 | NA/NA | One drop/time, twice daily/1 drop/time, 4 times daily | Tacrolimus/ tobramycin dexamethasone | 1 W | 15.25±1.69/ 15.19±1.57 | 11.21±2.25/ 11±2.20 | Signs, symptoms, |
C, Control group; T, Trial group; W, weeks.